HOME >> MEDICINE >> NEWS
Researchers develop 'genetic blueprint' to predict response to esophageal cancer treatments

ANAHEIM - For the first time, researchers appear to be able to use a comprehensive panel of genetic variants to predict how a patient with esophageal cancer will respond to a spectrum of cancer treatments.

At the annual meeting of the American Association for Cancer Research (AACR), researchers from The University of Texas M. D. Anderson Cancer Center report that six different gene variants can predict an improved outcome in patients treated with two different chemotherapy drugs and/or with radiation therapy.

For example, the researchers say that a combination of several gene variants in patients treated with one type of chemotherapy (5-FU) more than doubled survival to 51 months, compared to 25 months in patients treated with the same drug who did not have these variants.

They say the findings represent a leap forward in the goal to provide tailored therapy to individual patients because it offers a genetic blueprint for gauging the potential effectiveness of all common esophageal cancer treatment, not just an analysis of how one or two "candidate" genes respond to a single treatment.

"Our data strongly suggest that combined pathway-based analysis may provide powerful clinical outcome predictors for esophageal cancer as well as for other cancers," says the study's lead author Xifeng Wu, M.D., Ph.D., a professor in the Department of Epidemiology.

"This points to a promising new direction for cancer pharmacogenetics," she says. "Our hope is to have a gene chip one day that can analyze a patient's genetic makeup and help physicians predict response to a wide variety of therapeutic drugs before treatment even begins."

Esophageal cancer is highly aggressive; approximately 14,520 new esophageal cancer cases and 13,570 associated deaths are expected in 2005, according to the American Cancer Society. Almost half of new cases are diagnosed at an advanced stage, when the five-year survival rate is just 14 percent. Surgery
'"/>

Contact: Nancy Jensen
nwjensen@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
19-Apr-2005


Page: 1 2 3

Related medicine news :

1. Researchers suggest TB screening for all international adoptees
2. Researchers find vitamin B1 deficiency key to vascular problems for diabetic patients
3. Researchers link metal ions to neurodegenerative disease
4. Researchers develop criteria to detect bone mass deficiencies in children with chronic diseases
5. Researchers call for investigation into links between khat use and psychiatric disorders
6. Researchers use MRI to predict recovery after spinal cord injury
7. Researchers find deadly prescription drug effects 6 years before FDA
8. Researchers investigate impact of lifestyle on GI health
9. Researchers begin randomized double-blind trial of airway bypass treatment for emphysema
10. Researchers discover how antibiotic inhibits bacterial growth
11. Researchers urge caution in using ESAs for cancer-related anemia

Post Your Comments:
(Date:10/22/2014)... October 22, 2014 Lintelus, Inc., an ... Vice President of Sales, will be speaking on the ... Technology Expo on October 28, at the Holiday Inn ... a booth as well as a Tech Demo at ... can create a more engaging event experience. , The ...
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
(Date:10/22/2014)... By Maureen Salamon ... -- Black women undergoing in vitro fertilization (IVF) are only ... using the popular assisted reproduction technique, new research indicates, and ... In the study, about 31 percent of white patients ... black patients. Analyzing more than 4,000 IVF cycles over ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... to increased blood pressure, according to a new study. ... pressure for young adult women or for teenagers, according to ... or moderately, their risk of high blood pressure was cut ... in older adult men and women," said lead researcher Dr. ...
(Date:10/22/2014)... Measures taken by Firestone officials at the company,s ... the spread of the disease there and could prove ... Co. provides health services to about 80,000 employees, retirees, ... Between Aug. 1 and Sept. 23, there were ... people. That incidence rate of 0.09 percent was much ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
(Date:10/22/2014)... Oct. 22, 2014  Recently published clinical studies of ... already substantial database of evidence. This data has led ... Stretta therapy for sufferers of refractory GERD. ... supporting Stretta therapy as a safe and effective ... Stretta therapy available to nearly 50 million Americans. The ...
(Date:10/20/2014)... 2014  PneumRx, Inc. ( www.pneumrx.com ), a leader ... of enrollment in their RENEW Study, nearly 3 months ... FDA-approved IDE pivotal trial for the PneumRx RePneu Coil ... was anticipated that the study, which began enrolling subjects ... the end of 2014 to enroll 315 patients.  Instead, ...
(Date:10/20/2014)... ENGLEWOOD, Colo. , Oct. 20, 2014 /PRNewswire/ ... Inc. (NYSE MKT: AMPE), today announced that its ... the clinical and research potential for its novel ... oxidation-reduction potential (ORP) in the body in response ... clinical value of ORP as a clinical marker ...
Breaking Medicine Technology:Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5
Cached News: